Sena Ardicli, Huseyn Babayev, Lihong Chang, Ozge Ardicli, Can Zeyneloglu, Yagiz Pat, Duygu Yazici, Xiaoqing Liu, Ezgi Irem Bektas, Carina Beha, Halil I. Akyildiz, Nazrin B. Mammadova, Muhammed Emin Sari, Beate Rückert, Raja Dhir, Ismail Ogulur, Kari C. Nadeau, Mubeccel Akdis, Cezmi A. Akdis
{"title":"Polyethylene Terephthalate Micro and Nanoplastics Induce Oxidative and Endoplasmic Reticulum Stress, Compromising Intestinal Epithelial Integrity and Viability","authors":"Sena Ardicli, Huseyn Babayev, Lihong Chang, Ozge Ardicli, Can Zeyneloglu, Yagiz Pat, Duygu Yazici, Xiaoqing Liu, Ezgi Irem Bektas, Carina Beha, Halil I. Akyildiz, Nazrin B. Mammadova, Muhammed Emin Sari, Beate Rückert, Raja Dhir, Ismail Ogulur, Kari C. Nadeau, Mubeccel Akdis, Cezmi A. Akdis","doi":"10.1111/all.70291","DOIUrl":"https://doi.org/10.1111/all.70291","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"9 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147507911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Suhrkamp, T. Heidland, C. Saft, A. K. Kamps, S. Edenhart, O. Kniemeyer, W. Francuzik, S. Weidinger, P. Bacher, C. Bang, G. Heine
{"title":"Malassezia ‐Induced Type 2 Immunity in Head Neck Shoulder Type Atopic Dermatitis","authors":"I. Suhrkamp, T. Heidland, C. Saft, A. K. Kamps, S. Edenhart, O. Kniemeyer, W. Francuzik, S. Weidinger, P. Bacher, C. Bang, G. Heine","doi":"10.1111/all.70302","DOIUrl":"https://doi.org/10.1111/all.70302","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"235 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dominika Ambrożej, Karolina Dumycz, Wojciech Feleszko
{"title":"Early‐Life Viral Infections as Architects of Asthma Susceptibility","authors":"Dominika Ambrożej, Karolina Dumycz, Wojciech Feleszko","doi":"10.1111/all.70315","DOIUrl":"https://doi.org/10.1111/all.70315","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"9 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background IL‐33 levels are elevated in the airways of patients with eosinophilic diseases, and IL‐33 receptor expression on eosinophils is upregulated in type 2‐high environments. However, the role of IL‐33 in the regulation of human eosinophils remains unclear. Objective To elucidate the inflammatory effects of IL‐33 on the cellular function of human eosinophils. Methods Blood eosinophils were stimulated with IL‐33, TNF‐α, oxidised low‐density lipoprotein (oxLDL) and complement fragments (C3a and C5a). Multi‐omics analyses, including transcriptomics and proteomics, were performed. Extracellular trap formation (ETosis) was assessed by SYTOX nucleic acid staining and was visualised by immunofluorescence and transmission electron microscopy. Results Multi‐omics analyses revealed an IL‐33‐ and TNF‐α‐induced inflammatory gene signature characterised by the upregulation of cell surface markers (oxLDL receptor 1, CD22, CD4 and ICAM‐1) and inflammatory mediators (C3, CCL3/4 and IL1A/B). CD22 upregulation was specific to IL‐33 stimulation. Eosinophils derived from nasal polyps exhibited a gene expression profile similar to that of IL‐33‐stimulated eosinophils. Functional assays demonstrated that oxLDL and complement fragments differentially prolonged eosinophil survival and altered the expression of adhesion molecules. OxLDL‐ and complement fragment‐induced gene signatures were partly detected in eosinophils derived from nasal polyps. Furthermore, IL‐33 triggered ETosis via NADPH oxidase, mitogen‐activated protein kinase and phosphoinositide 3‐kinase pathways. Conclusions IL‐33, in conjunction with oxLDL and the complement cascade, induces inflammatory changes in eosinophils, promoting an ETosis‐prone phenotype. These pathways represent potential therapeutic targets in refractory eosinophilic diseases.
{"title":"IL ‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways","authors":"Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga","doi":"10.1111/all.70313","DOIUrl":"https://doi.org/10.1111/all.70313","url":null,"abstract":"Background IL‐33 levels are elevated in the airways of patients with eosinophilic diseases, and IL‐33 receptor expression on eosinophils is upregulated in type 2‐high environments. However, the role of IL‐33 in the regulation of human eosinophils remains unclear. Objective To elucidate the inflammatory effects of IL‐33 on the cellular function of human eosinophils. Methods Blood eosinophils were stimulated with IL‐33, TNF‐α, oxidised low‐density lipoprotein (oxLDL) and complement fragments (C3a and C5a). Multi‐omics analyses, including transcriptomics and proteomics, were performed. Extracellular trap formation (ETosis) was assessed by SYTOX nucleic acid staining and was visualised by immunofluorescence and transmission electron microscopy. Results Multi‐omics analyses revealed an IL‐33‐ and TNF‐α‐induced inflammatory gene signature characterised by the upregulation of cell surface markers (oxLDL receptor 1, CD22, CD4 and ICAM‐1) and inflammatory mediators (C3, CCL3/4 and IL1A/B). CD22 upregulation was specific to IL‐33 stimulation. Eosinophils derived from nasal polyps exhibited a gene expression profile similar to that of IL‐33‐stimulated eosinophils. Functional assays demonstrated that oxLDL and complement fragments differentially prolonged eosinophil survival and altered the expression of adhesion molecules. OxLDL‐ and complement fragment‐induced gene signatures were partly detected in eosinophils derived from nasal polyps. Furthermore, IL‐33 triggered ETosis via NADPH oxidase, mitogen‐activated protein kinase and phosphoinositide 3‐kinase pathways. Conclusions IL‐33, in conjunction with oxLDL and the complement cascade, induces inflammatory changes in eosinophils, promoting an ETosis‐prone phenotype. These pathways represent potential therapeutic targets in refractory eosinophilic diseases.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"33 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rafael José Vieira, Bernardo Sousa‐Pinto, Jean Bousquet, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, Anna Bedbrook, Wienczyslawa Czarlewski, Maria Jose Torres, Mohamed H. Shamji, Mário Morais‐Almeida, G. Walter Canonica, Leticia de las Vecillas, Mark S. Dykewicz, Cristina Jacomelli, Ludger Klimek, Lucas Leemann, Olga Lourenço, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Marine Savouré, Sanna K. Toppila‐Salmi, Maria Teresa Ventura, Juan José Yepes‐Nuñez, Alvaro A. Cruz, Giorgio Ciprandi, Bilun Gemicioglu, Mattia Giovannini, Brigita Gradauskiene, Tuomas Jartti, Miloš Jeseňák, Piotr Kuna, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Amir H. A. Latiff, Yousser Mohammad, Ken Ohta, Padukudru A. Mahesh, Isabella Pali‐Schöll, Oliver Pfaar, Frederico S. Regateiro, Nicolas Roche, Luís Taborda‐Barata, Charlotte Suppli Ulrik, Giovanni Viegi, Luo Zhang, Tari Haahtela, Ivan Cherrez‐Ojeda, Juan Carlos Ivancevich, Nikolai Khaltaev, Arzu Yorgancioglu, Baharudin Abdullah, Mona Al‐Ahmad, Maryam Ali Al‐Nesf, Rita Amaral, Julijana Asllani, Karl‐C. Bergmann, Jonathan A. Bernstein, Michael S. Blaiss, Elina Toskala, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Alessandro Fiocchi, Antonio F. M. Giuliano, George Christoff, Ieva Cirule, Jaime Correia de Sousa, Elisio M. Costa, Philippe Devillier, Elham Hossny, Tomohisa Iinuma, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Kazi S. Bennoor, Helga Kraxner, Inger Kull, Marek Kulus, Maciej Kupczyk, Andriy Kurchenko, Stefania La Grutta, Neven Miculinic, Lan Le Thi Tuyet, Sang Min Lee, Stephen Montefort, Andre Moreira, Joaquim Mullol, Rachel Nadif, Alla Nakonechna, Hugo E. Neffen, Marek Niedoszytko, Robyn E. O'Hehir, Ismail Ogulur, Yoshitaka Okamoto, Heidi Olze, Oscar Palomares, Petr Panzner, Vincenzo Patella, Constantinos Pitsios, Francesca Puggioni, Santiago Quirce, Agné Ramonaité, Maria Susana Repka‐Ramirez, Graham Roberts, Karla Robles‐Velasco, Menachem Rottem, Marianella Salapatas, Joaquin Sastre, Nicola Scichilone, Juan‐Carlos Sisul, Dirceu Solé, Manuel E. Soto‐Martinez, Milan Sova, Pongsakorn Tantilipikorn, Ana Todo‐Bom, Vladyslav Tsaryk, Ioanna Tsiligianni, Marilyn Urrutia‐Pereira, Erkka Valovirta, Tuula Vasankari, Dana Wallace, De Yun Wang, Margitta Worm, Osman M. Yusuf, Sara Gil‐Mata, Manuel Marques‐Cruz, Bassam Mahboub, Antonino Romano, Werner Aberer, Maria Cristina Artesani, Elena Azzolini, Bruno Barreto, Joan Bartra, Sven Becker, Bianca Beghe, Attilio Boner, Ewa Borowiack, Jacques Bouchard, Luisa Brussino, Roland Buhl, Francesco Catamerò, Denis Charpin, Niels H. Chavannes, Marta Chełmińska, Lei Cheng, Ekaterine Chkhartishvili, Seong H. Cho, Herberto Jose Chong‐Neto, Derek K. Chu, Cemal Cingi, Enrico Compalati, Raquel Albuquerque Costa, Biljana Cvetkovski, Victoria Cardona, Gennaro D'Amato, Janet M. Davies, Danilo Di Bona, Sandra N. Gonzalez Diaz, Maria V. Dimou, Maria Doulaptsi, Renato Ferreira‐da‐Silva, Radoslaw Gawlik, Mario Calvo‐Gil, Maximiliano R. Gómez, Maia Gotua, Christos Grigoreas, Maria Antonieta Guzman, Rachel House, Michael Hyland, Despo Ierodiakonou, Aspasia Karavelia, Paul Keith, Marta Kisiel, Tanja Soklic Kosak, Mitja Kosnik, Ilgim Vardaloglu Koyuncu, Vicky Kritikos, Justyna Litynska, Carlo Lombardi, Gilles Louis, Xin Luo, Matteo Martini, Cem Meço, Eris Mesonjesi, Florin Mihaltan, Marcin Moniuszko, Robert N. Naclerio, Sophia Neisinger, Markus Ollert, Michal Ordak, Giovanni Paoletti, Elena Parmelli, Edgar Arturo Perdomo‐Flores, Henrique Pereira, José Miguel Fuentes Pérez, Nhan Pham‐Thi, Emmanuel Prokopakis, Inês Ribeiro‐Vaz, Giovanni Rolla, Jan Romantowski, Philippe Rombaux, Philip W. Rouadi, Dermot Ryan, Ewelina Sadowska, Daiju Sakurai, Laila Salameh, Elie Serrano, Jane Da Silva, Michael B. Soyka, Krzysztof Specjalski, Vesna Tomic‐Spiric, Katarina Stevanovic, Abirami Subramaniam, Tuuli Thomander, Wu Tong, Martina Vachova, Marianne van Hage, Martin Wagenmann, Fanny Wai San Ko, Pascal Werminghaus, Paraskevi Vicky Xepapadaki, Yi‐Kui Xiang, Qintai Yang, He Zhang, Jaron Zuberbier, João A. Fonseca
Background Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments. Methods The ARIA‐EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence‐to‐decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion This ARIA‐EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.
{"title":"Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part II —Guidelines on Oral and Ocular Treatments","authors":"Rafael José Vieira, Bernardo Sousa‐Pinto, Jean Bousquet, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, Anna Bedbrook, Wienczyslawa Czarlewski, Maria Jose Torres, Mohamed H. Shamji, Mário Morais‐Almeida, G. Walter Canonica, Leticia de las Vecillas, Mark S. Dykewicz, Cristina Jacomelli, Ludger Klimek, Lucas Leemann, Olga Lourenço, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Marine Savouré, Sanna K. Toppila‐Salmi, Maria Teresa Ventura, Juan José Yepes‐Nuñez, Alvaro A. Cruz, Giorgio Ciprandi, Bilun Gemicioglu, Mattia Giovannini, Brigita Gradauskiene, Tuomas Jartti, Miloš Jeseňák, Piotr Kuna, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Amir H. A. Latiff, Yousser Mohammad, Ken Ohta, Padukudru A. Mahesh, Isabella Pali‐Schöll, Oliver Pfaar, Frederico S. Regateiro, Nicolas Roche, Luís Taborda‐Barata, Charlotte Suppli Ulrik, Giovanni Viegi, Luo Zhang, Tari Haahtela, Ivan Cherrez‐Ojeda, Juan Carlos Ivancevich, Nikolai Khaltaev, Arzu Yorgancioglu, Baharudin Abdullah, Mona Al‐Ahmad, Maryam Ali Al‐Nesf, Rita Amaral, Julijana Asllani, Karl‐C. Bergmann, Jonathan A. Bernstein, Michael S. Blaiss, Elina Toskala, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Alessandro Fiocchi, Antonio F. M. Giuliano, George Christoff, Ieva Cirule, Jaime Correia de Sousa, Elisio M. Costa, Philippe Devillier, Elham Hossny, Tomohisa Iinuma, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Kazi S. Bennoor, Helga Kraxner, Inger Kull, Marek Kulus, Maciej Kupczyk, Andriy Kurchenko, Stefania La Grutta, Neven Miculinic, Lan Le Thi Tuyet, Sang Min Lee, Stephen Montefort, Andre Moreira, Joaquim Mullol, Rachel Nadif, Alla Nakonechna, Hugo E. Neffen, Marek Niedoszytko, Robyn E. O'Hehir, Ismail Ogulur, Yoshitaka Okamoto, Heidi Olze, Oscar Palomares, Petr Panzner, Vincenzo Patella, Constantinos Pitsios, Francesca Puggioni, Santiago Quirce, Agné Ramonaité, Maria Susana Repka‐Ramirez, Graham Roberts, Karla Robles‐Velasco, Menachem Rottem, Marianella Salapatas, Joaquin Sastre, Nicola Scichilone, Juan‐Carlos Sisul, Dirceu Solé, Manuel E. Soto‐Martinez, Milan Sova, Pongsakorn Tantilipikorn, Ana Todo‐Bom, Vladyslav Tsaryk, Ioanna Tsiligianni, Marilyn Urrutia‐Pereira, Erkka Valovirta, Tuula Vasankari, Dana Wallace, De Yun Wang, Margitta Worm, Osman M. Yusuf, Sara Gil‐Mata, Manuel Marques‐Cruz, Bassam Mahboub, Antonino Romano, Werner Aberer, Maria Cristina Artesani, Elena Azzolini, Bruno Barreto, Joan Bartra, Sven Becker, Bianca Beghe, Attilio Boner, Ewa Borowiack, Jacques Bouchard, Luisa Brussino, Roland Buhl, Francesco Catamerò, Denis Charpin, Niels H. Chavannes, Marta Chełmińska, Lei Cheng, Ekaterine Chkhartishvili, Seong H. Cho, Herberto Jose Chong‐Neto, Derek K. Chu, Cemal Cingi, Enrico Compalati, Raquel Albuquerque Costa, Biljana Cvetkovski, Victoria Cardona, Gennaro D'Amato, Janet M. Davies, Danilo Di Bona, Sandra N. Gonzalez Diaz, Maria V. Dimou, Maria Doulaptsi, Renato Ferreira‐da‐Silva, Radoslaw Gawlik, Mario Calvo‐Gil, Maximiliano R. Gómez, Maia Gotua, Christos Grigoreas, Maria Antonieta Guzman, Rachel House, Michael Hyland, Despo Ierodiakonou, Aspasia Karavelia, Paul Keith, Marta Kisiel, Tanja Soklic Kosak, Mitja Kosnik, Ilgim Vardaloglu Koyuncu, Vicky Kritikos, Justyna Litynska, Carlo Lombardi, Gilles Louis, Xin Luo, Matteo Martini, Cem Meço, Eris Mesonjesi, Florin Mihaltan, Marcin Moniuszko, Robert N. Naclerio, Sophia Neisinger, Markus Ollert, Michal Ordak, Giovanni Paoletti, Elena Parmelli, Edgar Arturo Perdomo‐Flores, Henrique Pereira, José Miguel Fuentes Pérez, Nhan Pham‐Thi, Emmanuel Prokopakis, Inês Ribeiro‐Vaz, Giovanni Rolla, Jan Romantowski, Philippe Rombaux, Philip W. Rouadi, Dermot Ryan, Ewelina Sadowska, Daiju Sakurai, Laila Salameh, Elie Serrano, Jane Da Silva, Michael B. Soyka, Krzysztof Specjalski, Vesna Tomic‐Spiric, Katarina Stevanovic, Abirami Subramaniam, Tuuli Thomander, Wu Tong, Martina Vachova, Marianne van Hage, Martin Wagenmann, Fanny Wai San Ko, Pascal Werminghaus, Paraskevi Vicky Xepapadaki, Yi‐Kui Xiang, Qintai Yang, He Zhang, Jaron Zuberbier, João A. Fonseca","doi":"10.1111/all.70305","DOIUrl":"https://doi.org/10.1111/all.70305","url":null,"abstract":"Background Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments. Methods The ARIA‐EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence‐to‐decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion This ARIA‐EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"35 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to \"Epicutaneous Sensitization in the Development of Food Allergy: What Is the Evidence and How Can This be Prevented?\"","authors":"","doi":"10.1111/all.70320","DOIUrl":"https://doi.org/10.1111/all.70320","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"19 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mireille C Melles,Johannes C C M In 't Veen,Dirk-Jan Slebos,Frits M E Franssen,Marlies van Dijk,Pieter-Paul W Hekking
{"title":"Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations.","authors":"Mireille C Melles,Johannes C C M In 't Veen,Dirk-Jan Slebos,Frits M E Franssen,Marlies van Dijk,Pieter-Paul W Hekking","doi":"10.1111/all.70300","DOIUrl":"https://doi.org/10.1111/all.70300","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"17 2 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.
{"title":"Chinese Position Paper on Biologic Therapy for Allergic Rhinitis.","authors":"Yuan Zhang,Jingyun Li,Xian Li,Menglin Wang,Xiangli Yang,Li Shi,Zhiwei Cao,Yan Feng,Weiwei Liu,Zhendong Xu,Ruixia Ma,Xiaoping Gao,Wen Liu,Jinmei Xue,Xiaoyong Ren,Xuezhong Li,Xicheng Song,Yi Yang,Fang Quan,Lei Cheng,Weihong Jiang,Huabin Li,Jian Li,Huanhai Liu,Jianfeng Liu,Zheng Liu,Wei Lv,Qianhui Qiu,Xiangdong Wang,Yu Xu,Yuanteng Xu,Qintai Yang,Yucheng Yang,Jing Ye,Hongmeng Yu,Dongdong Zhu,Chengshuo Wang,Luo Zhang","doi":"10.1111/all.70312","DOIUrl":"https://doi.org/10.1111/all.70312","url":null,"abstract":"Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"17 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sabine Dölle-Bierke,Alejandro Gonzalo-Fernández,Dominique Sabouraud-Leclerc,Laura Barreales-Tolosa,Barbara Ballmer-Weber,Simona Belohlavkova,Maria B Bilò,Ruta Dubakiene,Karin Hartmann,Monika Jedrzejczak-Czechowicz,Thuy-My Le,Lars Lange,Nikolaos G Papadopoulos,Guillaume Pouessel,Isabel Reig,Athanasios Sinaniotis,E N Clare Mills,Margitta Worm,Montserrat Fernández-Rivas
BACKGROUNDThe consumption of plant-based food has lately largely increased, raising concerns about allergic reactions from ingredients which are currently not subject to mandatory labelling.METHODSWe analysed the frequency and severity of allergic reactions to non-mandatory labelled allergenic foods (pea, lentil, bean, chickpea, fenugreek, pine nut, sunflower-, poppy-, pumpkin seed, buckwheat) from two large European cohorts: The Anaphylaxis Registry (NORA) and EuroPrevall outpatient clinic study. Severity was assessed using the Food Allergy Severity Score (FASS) and compared with reactions to mandatory labelled allergenic foods.RESULTSAmong 589 reactions from both cohorts, sunflower seed was the most frequent trigger (n = 126). In NORA, pine nut (1.0% of food-induced allergic reactions) was most common followed by pea and buckwheat (0.7% each); in EuroPrevall, sunflower seed (1.2%), poppy seed (0.6%) and lentil (0.6%) predominated. After adjusting for age and sex, the severity of reactions to mandatory labelled seeds and legumes (excluding peanut) were not different (nFASS median: 4.39 vs. 4.43 and 4.56 vs. 4.49). Whereas, cereal-induced reactions (6.47) were significantly more severe than buckwheat (4.77). In Nora, the number of reactions to fenugreek and pumpkin seed were 7.4- and 3.7-fold higher in 2015-2022 versus 2007-2014.CONCLUSIONNon-mandatory labelled allergenic foods were identified to cause severe allergic reactions in two large European cohorts. The frequent involvement of sunflower seed, pine nut, pea and lentil, but also rising numbers of reactions to fenugreek and pumpkin seed, indicates their potential risk. These allergenic foods warrant close monitoring and consideration in future allergen labelling revisions.
植物性食品的消费量最近大幅增加,引起了人们对目前没有强制性标签的成分的过敏反应的担忧。方法:我们分析了来自两个大型欧洲队列的非强制性标签过敏性食物(豌豆、扁豆、豆类、鹰嘴豆、胡芦巴、松仁、向日葵、罂粟、南瓜子、荞麦)过敏反应的频率和严重程度:过敏反应登记处(NORA)和EuroPrevall门诊研究。使用食物过敏严重程度评分(FASS)评估严重程度,并将其与对强制标签过敏食品的反应进行比较。结果在两个队列的589例反应中,葵花籽是最常见的触发因素(n = 126)。在NORA中,松子(1.0%的食物引起的过敏反应)最常见,其次是豌豆和荞麦(各0.7%);EuroPrevall以葵花籽(1.2%)、罂粟籽(0.6%)和扁豆(0.6%)为主。在调整了年龄和性别后,对强制性标签种子和豆类(不包括花生)的反应严重程度没有差异(nFASS中位数:4.39 vs. 4.43, 4.56 vs. 4.49)。而谷物引起的反应(6.47)明显比荞麦(4.77)严重。在诺拉,2015-2022年对葫芦巴和南瓜籽的反应数量比2007-2014年高7.4倍和3.7倍。结论:在两个大型欧洲队列中,非强制性标签致敏性食品被确定为引起严重过敏反应。葵花籽、松子、豌豆和扁豆的频繁涉及,以及葫芦巴和南瓜籽的反应数量也在增加,表明它们的潜在风险。这些致敏食物需要密切监测,并在未来修订过敏原标签时加以考虑。
{"title":"Frequency and Severity of Allergic Reactions to Non-Mandatory Labelled Allergenic Foods-Data From Two Large European Cohorts.","authors":"Sabine Dölle-Bierke,Alejandro Gonzalo-Fernández,Dominique Sabouraud-Leclerc,Laura Barreales-Tolosa,Barbara Ballmer-Weber,Simona Belohlavkova,Maria B Bilò,Ruta Dubakiene,Karin Hartmann,Monika Jedrzejczak-Czechowicz,Thuy-My Le,Lars Lange,Nikolaos G Papadopoulos,Guillaume Pouessel,Isabel Reig,Athanasios Sinaniotis,E N Clare Mills,Margitta Worm,Montserrat Fernández-Rivas","doi":"10.1111/all.70308","DOIUrl":"https://doi.org/10.1111/all.70308","url":null,"abstract":"BACKGROUNDThe consumption of plant-based food has lately largely increased, raising concerns about allergic reactions from ingredients which are currently not subject to mandatory labelling.METHODSWe analysed the frequency and severity of allergic reactions to non-mandatory labelled allergenic foods (pea, lentil, bean, chickpea, fenugreek, pine nut, sunflower-, poppy-, pumpkin seed, buckwheat) from two large European cohorts: The Anaphylaxis Registry (NORA) and EuroPrevall outpatient clinic study. Severity was assessed using the Food Allergy Severity Score (FASS) and compared with reactions to mandatory labelled allergenic foods.RESULTSAmong 589 reactions from both cohorts, sunflower seed was the most frequent trigger (n = 126). In NORA, pine nut (1.0% of food-induced allergic reactions) was most common followed by pea and buckwheat (0.7% each); in EuroPrevall, sunflower seed (1.2%), poppy seed (0.6%) and lentil (0.6%) predominated. After adjusting for age and sex, the severity of reactions to mandatory labelled seeds and legumes (excluding peanut) were not different (nFASS median: 4.39 vs. 4.43 and 4.56 vs. 4.49). Whereas, cereal-induced reactions (6.47) were significantly more severe than buckwheat (4.77). In Nora, the number of reactions to fenugreek and pumpkin seed were 7.4- and 3.7-fold higher in 2015-2022 versus 2007-2014.CONCLUSIONNon-mandatory labelled allergenic foods were identified to cause severe allergic reactions in two large European cohorts. The frequent involvement of sunflower seed, pine nut, pea and lentil, but also rising numbers of reactions to fenugreek and pumpkin seed, indicates their potential risk. These allergenic foods warrant close monitoring and consideration in future allergen labelling revisions.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"92 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}